Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Bio-sincerity Secures NMPA Clinical Trial Approval for BIOS0629-109, Novel XPO1 Inhibitor for Advanced Malignant Tumors

Fineline Cube Jul 3, 2026
Company Drug

Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older

Fineline Cube Jul 3, 2026
Company Drug

SSY Group’s Blonanserin and Paracetamol Approved by China’s NMPA

Fineline Cube Jun 21, 2022

China-based SSY Group Limited (HKG: 2005) has announced receiving market approvals from the National Medical...

Company Deals

Shanghai ShineYo Medical Device Secures RMB 100 Million in Series A Round

Fineline Cube Jun 21, 2022

Shanghai ShineYo Medical Device Co., Ltd, a company specializing in electrophysiology and peripheral intervention, has...

Company Deals R&D

Boehringer Ingelheim Venture Fund and Hong Kong Science Park Launch Co-Incubation Plan

Fineline Cube Jun 20, 2022

Germany-based pharmaceutical giant Boehringer Ingelheim’s venture fund (BIVF) and China-based Hong Kong Science & Technology...

Company Drug

Innovent Biologics’ Tyvyt Approved for First-Line Esophageal Squamous Cell Carcinoma

Fineline Cube Jun 20, 2022

The National Medical Products Administration (NMPA) website indicates that China-based Innovent Biologics, Inc. (HKG: 1801)...

Policy / Regulatory

China’s Seventh National Volume-based Procurement Round Kicks Off with Revised Rules

Fineline Cube Jun 20, 2022

China’s health authorities have resumed the seventh national volume-based procurement (VBP) round after a pandemic-related...

Company Deals

Shenzhen AXBio Closes USD 100 Million Series B Round for Sequencing Tech Expansion

Fineline Cube Jun 20, 2022

Shenzhen-based fourth-generation sequencing company Anxuyuan Biotechnology (shenzhen) Company Limited (AXBio) has reportedly secured close to...

Company Medical Device

Boston Scientific Launches Expect Airway Ultrasound Needle in China for Lung Cancer Diagnosis

Fineline Cube Jun 20, 2022

US-based Boston Scientific Corporation (NYSE: BSX) has announced the official market launch of its Expect...

Company Deals

Iomics Biosciences Secures RMB 100 Million for Proteomics and Spatialomics Expansion

Fineline Cube Jun 20, 2022

Beijing-based Iomics Biosciences Co., Ltd, a developer of gene sequencing and diagnostic equipment, has reportedly...

Company Drug

InnoCare and Keymed Biosciences’ CCR8-Targeted mAb CM369 Accepted by NMPA

Fineline Cube Jun 20, 2022

China-based InnoCare (HKG: 9969) and Keymed Biosciences Inc. (HKG: 2162) announced that an Investigational New...

Policy / Regulatory

CDE Releases 58th and 59th Batches of Chemical Generic Reference Preparations

Fineline Cube Jun 20, 2022

The Center for Drug Evaluation (CDE) has released the 58th and 59th batches of chemical...

Company Deals

Shenzhen’s LWPOCT Secures RMB 100 Million in Series A Round for CDMO Expansion

Fineline Cube Jun 20, 2022

Shenzhen-based medical devices and reagents manufacturer Shenzhen Living Water POCT Co., LTd (LWPOCT) has reportedly...

Company Drug

Henlius Biotech Begins Global Phase III Trial for Denosumab Biosimilar HLX14

Fineline Cube Jun 20, 2022

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced the first patient dosing in a...

Company Drug

Cellular Biomedicine Group’s C-CAR039 Receives NMPA Approval for B-Cell NHL Study

Fineline Cube Jun 20, 2022

China-based Cellular Biomedicine Group Inc. (CBMG), a private company following a merger deal in February...

Company Deals

Global Cord Blood Corp’s Cellenkos Gets FDA Nod for Myelofibrosis Trial

Fineline Cube Jun 20, 2022

Global Cord Blood Corporation (GCBC; NYSE: CO) announced receiving Investigational New Drug (IND) approval from...

Company Deals

Hangzhou Tongee Medical Closes RMB 100 Million Series B Round for Gastric Bypass Stent

Fineline Cube Jun 19, 2022

Hangzhou Tongee Medical Technology Co., Ltd, a Chinese device maker specializing in metabolic disease treatments,...

Policy / Regulatory

Scotland Reports First Case of ASHep-UA in Children, WHO Issues Guidelines

Fineline Cube Jun 19, 2022

Scotland recorded its first case of acute severe hepatitis of unknown etiology in children (ASHep-UA)...

Company Drug R&D

Walvax’s mRNA Vaccine AWcorna Shows Superior Immune Response in Phase III Trial

Fineline Cube Jun 19, 2022

Walvax Biotechnology Co., Ltd’s (SHE: 300142) mRNA vaccine against SARS-CoV-2, named AWcorna, has reached the...

R&D

Tianhe-2 Supercomputer Aids Drug Discovery with Deep-Learning Biosynthetic Tool

Fineline Cube Jun 19, 2022

China’s Tianhe-2 supercomputer, ranked among the top-10 fastest computers globally, has demonstrated potential in enhancing...

Company Deals

Shanghai Pharmaceuticals Licenses Benapenem and Plazomicin from Xuanzhu Bio for Greater China

Fineline Cube Jun 19, 2022

China-based pharmaceutical giant Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) announced a licensing agreement with compatriot...

Company Drug

Sichuan Meida’s Phentolamine Gains Priority Review for Pheochromocytoma Treatment

Fineline Cube Jun 19, 2022

The Center for Drug Evaluation (CDE) website indicates that Sichuan Meida Kangjiale Pharmaceutical Co., Ltd’s...

Posts pagination

1 … 684 685 686 … 690

Recent updates

  • Bio-sincerity Secures NMPA Clinical Trial Approval for BIOS0629-109, Novel XPO1 Inhibitor for Advanced Malignant Tumors
  • Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older
  • Ocumension Therapeutics Secures NMPA Approval for OT-502, China’s First Single-Dose Sustained-Release Intraocular Steroid for Postoperative Inflammation
  • Hotgen Biotech Launches AI Subsidiary to Transform Small Nucleic Acid Drug Discovery
  • Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Bio-sincerity Secures NMPA Clinical Trial Approval for BIOS0629-109, Novel XPO1 Inhibitor for Advanced Malignant Tumors

Company Drug

Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older

Company Drug

Ocumension Therapeutics Secures NMPA Approval for OT-502, China’s First Single-Dose Sustained-Release Intraocular Steroid for Postoperative Inflammation

Company

Hotgen Biotech Launches AI Subsidiary to Transform Small Nucleic Acid Drug Discovery

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.